Insider Selling: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Director Sells $332,300.00 in Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Director Steven C. Gilman sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 22nd. The shares were sold at an average price of $33.23, for a total transaction of $332,300.00. Following the completion of the sale, the director now directly owns 17,796 shares of the company’s stock, valued at approximately $591,361.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

MNTA stock opened at $30.00 on Friday. The stock has a market capitalization of $3.53 billion, a price-to-earnings ratio of -10.71 and a beta of 1.51. Momenta Pharmaceuticals, Inc. has a 1 year low of $9.92 and a 1 year high of $39.88. The stock’s fifty day moving average is $34.21 and its two-hundred day moving average is $30.40.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.14. The company had revenue of $8.89 million for the quarter, compared to analysts’ expectations of $4.08 million. Momenta Pharmaceuticals had a negative return on equity of 80.37% and a negative net margin of 994.16%. Analysts predict that Momenta Pharmaceuticals, Inc. will post -1.61 EPS for the current fiscal year.

Several research firms have recently commented on MNTA. Wells Fargo & Co increased their target price on Momenta Pharmaceuticals from $40.00 to $48.00 and gave the company an “overweight” rating in a research note on Monday, June 15th. ValuEngine cut Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. Stifel Nicolaus reiterated a “buy” rating on shares of Momenta Pharmaceuticals in a research note on Wednesday, June 24th. JPMorgan Chase & Co. increased their target price on Momenta Pharmaceuticals from $37.00 to $42.00 and gave the company an “overweight” rating in a research note on Tuesday, June 16th. Finally, Piper Sandler restated a “buy” rating and set a $45.00 price objective on shares of Momenta Pharmaceuticals in a research note on Monday, June 15th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $43.00.

A number of hedge funds have recently bought and sold shares of the business. Candriam Luxembourg S.C.A. bought a new stake in Momenta Pharmaceuticals in the second quarter valued at $13,542,000. Oregon Public Employees Retirement Fund lifted its stake in Momenta Pharmaceuticals by 20.6% in the second quarter. Oregon Public Employees Retirement Fund now owns 47,954 shares of the biotechnology company’s stock valued at $1,595,000 after buying an additional 8,200 shares during the last quarter. New York State Teachers Retirement System increased its holdings in shares of Momenta Pharmaceuticals by 44.3% during the second quarter. New York State Teachers Retirement System now owns 178,389 shares of the biotechnology company’s stock valued at $5,935,000 after purchasing an additional 54,779 shares during the period. Robeco Institutional Asset Management B.V. acquired a new position in shares of Momenta Pharmaceuticals during the second quarter valued at $899,000. Finally, Handelsinvest Investeringsforvaltning acquired a new position in shares of Momenta Pharmaceuticals during the second quarter valued at $998,000. Institutional investors own 96.92% of the company’s stock.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Featured Article: How does a 12b-1 fee affect fund performance?

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.